SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE is well positioned because its 1Q26 results showed durable demand, with revenue of $52.6 million up 11% year over year, gross margin of 79.8%, and adjusted EBITDA turning positive at about $2.5 million to $2.6 million, all while management raised FY26 revenue guidance to $230 million to $233 million and gross margin guidance to 79%. Its outlook is supported by expanding adoption, as US procedure volume grew 9% and active physicians reached 1,650, with repeat utilization improving and rep productivity rising 11% to $2.2 million, suggesting more operating leverage as the company scales toward roughly 100 territories. The next leg of growth is backed by multiple catalysts, including the on-track 4Q26 launch of a third FDA breakthrough device, the Smith & Nephew partnership ramping in 2H26 and accelerating into 4Q, and potential reimbursement tailwinds from proposed DRG changes that could lift Granite adoption and revenue per case.

SI-BONE is exposed to several fundamental weaknesses that support a negative outlook, led by heavy reliance on a single orthopedic anatomical location and a business model highly sensitive to reimbursement coverage and payment-rate changes. If coverage or reimbursement becomes less favorable, adoption and utilization of its iFuse products could slow materially, while the SI joint fusion market may also fail to develop as expected because of reimbursement headwinds or difficulty changing physician behavior. Competition is another concern, as larger, more diversified players could intensify the market dynamic, and rapid sales-force expansion raises execution risk at a company that still lacks profitability.